 Bloomberg | Biogen Idec Q2 profits rise on strong Avonex sales PMLiVE Enrolment has been completed in the DECIDE trial of another MS drug candidate, daclizumab, with results expected in 2014, said Williams, while a phase IIa trial has got underway for STX-100, Biogen Idec's candidate treatment for idiopathic pulmonary ... Biogen Idec 2nd-qtr sales and earnings top analysts expectations |
